Last reviewed · How we verify
dexamethasone 700 ㎍ intravitreal implant
At a glance
| Generic name | dexamethasone 700 ㎍ intravitreal implant |
|---|---|
| Also known as | OZURDEX® |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
- A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated (PHASE4)
- Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema (PHASE2)
- A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion (PHASE3)
- A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion (PHASE3)
- A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)
- Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema (PHASE2)
- An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dexamethasone 700 ㎍ intravitreal implant CI brief — competitive landscape report
- dexamethasone 700 ㎍ intravitreal implant updates RSS · CI watch RSS
- Allergan portfolio CI